February 7, 2023

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

George Vradenburg – The Future of Alzheimer’s Advocacy Part 2

About This Episode

The Food and Drug Administration expedited approval of Lecanemab, a drug developed by Eisai and Biogen, that demonstrated positive results in slowing Alzheimer's disease. What does this mean for the future of Alzheimer’s advocacy?

In this episode of BrainStorm host Meryl Comer talks with George Vradenburg, Chairman and Co-Founder of UsAgainstAlzheimer’s, Convener of Global CEOi and Co-Convener with the World Economic Forum of the Davos Alzheimer’s Collaborative. They explore the implications of the approval of Lecanemab (or Leqembi) worldwide and whether the approval encourages healthy at-risk adults 50 plus to understand their dementia risk profile.

BrainStorm Feed

83

Doreen Monks – The Emotional Journey of Alzheimer’s and Dementia (part 2)

In this episode of BrainStorm, host Meryl Comer continues explore the challenges of dementia diagnosis in her interview with Doreen Monks, a former

LISTEN NOW
82

Doreen Monks – The Emotional Journey of Alzheimer’s and Dementia (part 1)

What if your life and career were upended with a diagnosis of Alzheimer’s only to learn eight years later that the diagnosis was wrong?  In th

LISTEN NOW
81

Tony Bennett's Daughters - Breaking Through the Silence of Alzheimer's

Learning about an Alzheimer’s diagnosis in your family is never easy.

LISTEN NOW